NMTC Fundamental Analysis - NEUROONE MEDICAL TECHNOLOGIE

Fundamental Rating

Overall NMTC gets a fundamental rating of 3 out of 10. We evaluated NMTC against 191 industry peers in the Health Care Equipment & Supplies industry. While NMTC seems to be doing ok healthwise, there are quite some concerns on its profitability. NMTC shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

NMTC had negative earnings in the past year.

In the past year NMTC has reported a negative cash flow from operations.

In the past 5 years NMTC always reported negative net income.

In the past 5 years NMTC always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -49.33%, NMTC is not doing good in the industry: 66.49% of the companies in the same industry are doing better.

Looking at the Return On Equity, with a value of -65.26%, NMTC is in line with its industry, outperforming 45.03% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-49.33%
ROE	-65.26%
ROIC	N/A

ROA(3y)-151.29%

ROA(5y)-173.14%

ROE(3y)-597.5%

ROE(5y)-520.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 70.14%, NMTC belongs to the best of the industry, outperforming 80.63% of the companies in the same industry.

NMTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	70.14%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NMTC does not have a ROIC to compare to the WACC, probably because it is not profitable.

NMTC has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, NMTC has more shares outstanding

Compared to 1 year ago, NMTC has a worse debt to assets ratio.

2.2 Solvency

NMTC has an Altman-Z score of 1.47. This is a bad value and indicates that NMTC is not financially healthy and even has some risk of bankruptcy.

NMTC has a Altman-Z score (1.47) which is comparable to the rest of the industry.

A Debt/Equity ratio of 0.13 indicates that NMTC is not too dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.13, NMTC is in the better half of the industry, outperforming 60.73% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.13
Debt/FCF	N/A
Altman-Z	1.47

ROIC/WACCN/A

WACC8.67%

2.3 Liquidity

A Current Ratio of 7.13 indicates that NMTC has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 7.13, NMTC belongs to the top of the industry, outperforming 86.91% of the companies in the same industry.

NMTC has a Quick Ratio of 5.80. This indicates that NMTC is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 5.80, NMTC belongs to the best of the industry, outperforming 85.86% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.13
Quick Ratio	5.8

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.67% over the past year.

Looking at the last year, NMTC shows a very strong growth in Revenue. The Revenue has grown by 142.96%.

NMTC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 143.22% yearly.

EPS 1Y (TTM)67.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%69.1%

Revenue 1Y (TTM)142.96%

Revenue growth 3Y143.22%

Revenue growth 5YN/A

Sales Q2Q%105.38%

3.2 Future

The Earnings Per Share is expected to grow by 19.96% on average over the next years. This is quite good.

The Revenue is expected to grow by 34.68% on average over the next years. This is a very strong growth

EPS Next Y72.62%

EPS Next 2Y28.64%

EPS Next 3Y19.96%

EPS Next 5YN/A

Revenue Next Year21.86%

Revenue Next 2Y26.81%

Revenue Next 3Y28.25%

Revenue Next 5Y34.68%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NMTC. In the last year negative earnings were reported.

Also next year NMTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

NMTC's earnings are expected to grow with 19.96% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y28.64%

EPS Next 3Y19.96%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NMTC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEUROONE MEDICAL TECHNOLOGIE

NASDAQ:NMTC (10/7/2025, 9:52:52 AM)

1.13

+0.13 (+13%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)08-14 2025-08-14/bmo

Earnings (Next)12-15 2025-12-15/amc

Inst Owners33.63%

Inst Owner Change0%

Ins Owners4.18%

Ins Owner Change-1.14%

Market Cap56.50M

Analysts85

Price Target2.27 (100.88%)

Short Float %0.07%

Short Ratio0.09

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)32.46%

Min EPS beat(2)23.75%

Max EPS beat(2)41.18%

EPS beat(4)3

Avg EPS beat(4)47.24%

Min EPS beat(4)-34.8%

Max EPS beat(4)158.82%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-25.92%

Min Revenue beat(2)-43.22%

Max Revenue beat(2)-8.62%

Revenue beat(4)1

Avg Revenue beat(4)-21.92%

Min Revenue beat(4)-88.49%

Max Revenue beat(4)52.66%

Revenue beat(8)2

Avg Revenue beat(8)-19.9%

Revenue beat(12)4

Avg Revenue beat(12)-5.35%

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)53.45%

PT rev (3m)53.45%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)11.54%

EPS NY rev (3m)17.86%

Revenue NQ rev (1m)-4.46%

Revenue NQ rev (3m)-5.76%

Revenue NY rev (1m)-1.95%

Revenue NY rev (3m)4.54%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	5.87
P/FCF	N/A
P/OCF	N/A
P/B	6.91
P/tB	6.95
EV/EBITDA	N/A

EPS(TTM)-0.15

EYN/A

EPS(NY)-0.15

Fwd EYN/A

FCF(TTM)-0.08

FCFYN/A

OCF(TTM)-0.08

OCFYN/A

SpS0.19

BVpS0.16

TBVpS0.16

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-49.33%
ROE	-65.26%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	70.14%
FCFM	N/A

ROA(3y)-151.29%

ROA(5y)-173.14%

ROE(3y)-597.5%

ROE(5y)-520.67%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.89

Health

		Industry Rank	Sector Rank
Debt/Equity	0.13
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	42.13%
Cap/Sales	1.16%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.13
Quick Ratio	5.8
Altman-Z	1.47

F-Score5

WACC8.67%

ROIC/WACCN/A

Cap/Depr(3y)158.25%

Cap/Depr(5y)160.45%

Cap/Sales(3y)9.28%

Cap/Sales(5y)12.64%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)67.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%69.1%

EPS Next Y72.62%

EPS Next 2Y28.64%

EPS Next 3Y19.96%

EPS Next 5YN/A

Revenue 1Y (TTM)142.96%

Revenue growth 3Y143.22%

Revenue growth 5YN/A

Sales Q2Q%105.38%

Revenue Next Year21.86%

Revenue Next 2Y26.81%

Revenue Next 3Y28.25%

Revenue Next 5Y34.68%

EBIT growth 1Y53.64%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-23.15%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y56.25%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y55.54%

OCF growth 3YN/A

OCF growth 5YN/A

NEUROONE MEDICAL TECHNOLOGIE (NMTC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens